scanX
Sun Pharmaceutical

Sun Pharmaceutical

1,763.90
+6.80
(0.39%)
hide
Key Fundamentals
Add Ratio
Market Cap
4,21,587.10 Cr
EPS
45.60
PE Ratio
40.19
Dividend Yield
0.91 %
Industry
Healthcare
52 Week High
1,910.00
52 Week Low
1,548.00
PB Ratio
5.42
Debt to Equity
0.04
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from36 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+86.11 %
+86.11 %
Hold
Hold+2.78 %
+2.78 %
Sell
Sell+11.11 %
+11.11 %
Forecast For
Actual

Company News

View All News
Caret
positive
AstraZeneca and Sun Pharma Partner to Expand Hyperkalemia Treatment Access in IndiaToday
AstraZeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership to market Sodium Zirconium Cyclosilicate (SZC) under different brand names - Lokelma by AstraZeneca and Gimli by Sun Pharma - for treating Hyperkalemia in India. The exclusive agreement aims to accelerate availability of the innovative treatment to more patients across India, with AstraZeneca retaining intellectual property rights and marketing authorization while both companies will promote and distribute the therapy.
positive
Sun Pharma Presents Positive Clinical Data for Obesity Drug Utreglutide at Medical Conferences5 days ago
Sun Pharmaceutical Industries presented clinical trial results for its investigational obesity drug utreglutide (GLO034) at Obesity Week 2025 and American Heart Association 2025 Scientific Sessions. The Phase 1b/2a studies showed significant outcomes: 13 weeks of treatment in individuals with obesity and MASLD demonstrated 6.8% body weight reduction and 6.8% waist circumference reduction at week 14. A separate 10-week study in overweight and obese individuals showed 6.8% body weight loss with 10% reductions in total cholesterol and LDL. In post-menopausal females with obesity, the drug achieved 8% weight loss at week 14 along with reduced liver fat content and blood pressure improvements. The most common adverse events were gastrointestinal including nausea, diarrhea, and vomiting, consistent with the drug class. GLO034 is a novel once-weekly GLP-1 receptor agonist being developed for obesity and type 2 diabetes treatment. Further clinical studies are planned to assess safety and efficacy.
neutral
Sun Pharma Partner Philogen Reports Mixed Results from Fibromun Cancer Drug Trial5 days ago
Sun Pharma's partner Philogen announced results from the FIBROSARCOMA Phase III clinical trial testing fibromun combined with doxorubicin for advanced soft tissue sarcoma treatment. The trial did not meet its primary endpoint of progression-free survival, but showed promising trends favoring the combination therapy. Median progression-free survival was 7.9 months for the combination versus 4.6 months for doxorubicin alone. Overall survival was 28.3 months for the combination arm compared to 19.6 months for doxorubicin alone, though survival data remains immature. Philogen plans to discuss results with European and US authorities and initiate a new Phase III trial with overall survival as the primary endpoint, expected to start in 2026. The company is also advancing other trials including FLASH, FIBROSARCUS, and multiple glioblastoma programs.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,763.90
#1 4,21,587.10
#7 40.19
#1 54,729.00
#6 9.71
#1 10,980
#8 2.89
72.45
Divis Laboratories
6,518.50
1,72,859.90
69.56
9,712.00
18.67
2,191
35.10
50.21
Torrent Pharmaceuticals
3,819.40
1,29,685.50
60.73
11,539.40
6.99
1,911
30.46
68.95
Cipla
1,535.60
1,23,756.00
22.77
28,409.50
7.12
5,291
3.71
49.08
Dr Reddys Laboratories
1,244.40
1,03,992.90
#1 18.11
33,741.20
16.73
5,725
-0.38
52.18
Zydus Life Science
934.75
95,033.80
18.89
23,511.00
18.55
4,615
34.60
34.63
Lupin
2,052.10
93,876.80
21.59
22,909.50
13.74
3,306
#1 72.75
64.79
Mankind Pharma
2,247.00
93,576.50
52.74
12,744.20
#1 20.90
2,007
-21.05
31.45
Aurobindo Pharma
1,236.90
71,003.00
20.93
32,345.60
9.43
3,484
3.81
75.20
Alkem Laboratories
5,723.00
68,421.10
28.40
13,458.30
3.70
2,216
10.98
64.57
Growth Rate
Revenue Growth
9.71 %
Net Income Growth
13.80 %
Cash Flow Change
15.96 %
ROE
5.43 %
ROCE
14.46 %
EBITDA Margin (Avg.)
9.26 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
6,493
6,691
6,973
7,260
7,622
8,164
7,869
7,805
7,050
6,319
6,845
6,727
7,014
7,339
7,198
7,850
7,326
8,472
8,150
8,159
8,180
7,640
9,019
9,124
8,575
9,822
9,780
10,247
9,500
10,646
10,894
11,274
11,099
11,990
12,297
12,407
12,419
13,057
13,618
13,903
13,429
14,251
14,875
Expenses
5,318
5,679
5,000
4,877
5,382
5,335
5,092
5,472
5,590
6,064
5,275
5,200
5,294
5,618
6,621
5,587
6,147
6,379
6,334
6,314
7,083
9,375
6,360
6,431
7,147
7,529
6,996
7,257
11,042
7,877
7,996
8,237
8,300
8,932
9,013
8,974
9,049
9,045
9,352
9,983
9,604
10,368
9,951
EBITDA
1,175
1,012
1,973
2,383
2,240
2,829
2,776
2,333
1,460
255
1,570
1,528
1,720
1,721
577
2,263
1,179
2,094
1,816
1,845
1,098
-1,736
2,659
2,693
1,427
2,293
2,784
2,990
-1,542
2,769
2,899
3,037
2,799
3,058
3,284
3,433
3,370
4,012
4,266
3,920
3,824
3,883
4,924
Operating Profit %
13 %
13 %
27 %
31 %
27 %
33 %
34 %
29 %
18 %
2 %
20 %
21 %
21 %
21 %
3 %
27 %
13 %
23 %
20 %
21 %
12 %
-25 %
25 %
27 %
16 %
22 %
27 %
26 %
-18 %
26 %
26 %
26 %
23 %
24 %
25 %
26 %
23 %
28 %
29 %
26 %
25 %
25 %
31 %
Depreciation
462
240
258
251
288
316
304
307
338
347
359
339
455
402
427
471
454
457
473
547
575
496
499
532
554
503
530
554
557
588
610
660
672
651
633
622
650
655
626
631
664
701
730
Interest
135
135
158
128
103
135
54
167
45
109
157
95
155
131
130
145
150
104
84
63
52
52
33
26
30
35
36
19
37
14
19
46
93
81
49
35
74
62
69
52
49
75
100
Profit Before Tax
591
872
1,572
2,040
2,087
2,628
2,930
2,102
1,389
-159
1,114
1,148
1,376
1,274
112
1,730
694
1,647
1,433
1,351
577
-2,184
2,206
2,163
903
1,804
2,287
2,466
-2,076
2,285
2,412
2,472
2,240
2,481
2,791
3,000
2,816
3,424
3,598
3,476
3,254
3,173
4,168
Tax
-596
115
272
100
424
360
458
380
3
164
113
792
-187
88
272
269
-26
151
270
332
85
242
263
250
61
400
200
340
152
191
157
291
257
476
406
440
157
563
561
563
1,100
880
1,043
Net Profit
1,186
757
1,299
1,940
1,663
2,268
2,471
1,722
1,386
-323
1,002
356
1,563
1,186
-160
1,461
721
1,497
1,163
1,019
493
-2,426
1,943
1,913
842
1,404
2,086
2,126
-2,227
2,093
2,256
2,181
1,983
2,006
2,385
2,561
2,659
2,861
3,037
2,913
2,154
2,293
3,125
EPS in ₹
3.70
2.30
4.30
6.40
5.90
8.50
9.30
6.10
5.20
-1.77
3.80
1.34
5.60
4.41
-1.12
5.18
2.65
5.78
4.43
3.81
1.67
-6.90
7.56
7.72
3.70
6.00
8.50
8.60
-9.50
8.60
9.40
9.00
8.30
8.40
9.90
10.50
11.10
11.80
12.70
12.10
9.00
9.50
13.00
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
49,028
55,530
61,410
64,516
64,694
68,253
67,667
69,808
80,744
85,500
92,101
Fixed Assets
12,683
15,872
17,675
18,853
21,837
22,847
21,553
22,665
24,065
23,248
22,586
Current Assets
29,122
29,941
32,954
31,636
31,069
31,654
30,442
34,865
39,862
43,433
52,594
Capital Work in Progress
2,039
2,175
2,801
2,465
1,411
1,220
1,567
1,287
4,973
5,354
6,644
Investments
2,117
1,830
1,192
7,143
7,903
10,143
9,612
12,849
14,824
15,026
18,354
Other Assets
32,189
35,653
39,742
36,056
33,544
34,042
34,935
33,007
36,881
41,872
44,517
Total Liabilities
49,028
55,530
61,410
64,516
64,694
68,253
67,667
69,808
80,744
85,500
92,101
Current Liabilities
16,353
13,144
17,887
19,864
17,340
15,706
16,146
17,208
19,906
16,984
18,194
Non Current Liabilities
4,186
5,319
3,093
2,454
2,632
3,421
2,041
1,533
1,522
1,390
1,420
Total Equity
28,489
37,068
40,431
42,198
44,723
49,125
49,480
51,066
59,316
67,126
72,486
Reserve & Surplus
25,383
32,741
36,400
38,074
41,169
45,025
46,223
47,771
55,755
63,427
71,978
Share Capital
207
241
240
240
240
240
240
240
240
240
240
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
2,927
848
611
-736
-844
-1,386
596
-1,765
116
4,662
983
Investing Activities
-1,502
-3,949
-4,186
-3,104
-310
-2,225
407
-5,556
-7,220
-763
-5,183
Operating Activities
5,616
6,686
7,082
3,907
2,196
6,555
6,170
8,985
4,959
12,135
14,072
Financing Activities
-1,187
-1,889
-2,285
-1,539
-2,731
-5,715
-5,981
-5,194
2,376
-6,710
-7,906
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.79 %
0.00 %
17.72 %
17.23 %
18.02 %
18.05 %
17.96 %
17.26 %
16.55 %
DIIs
21.59 %
21.93 %
21.67 %
20.94 %
19.94 %
19.57 %
18.60 %
19.14 %
19.24 %
19.75 %
19.67 %
17.97 %
18.83 %
19.28 %
18.61 %
18.55 %
18.70 %
19.50 %
20.24 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.34 %
7.21 %
6.79 %
6.68 %
6.49 %
6.31 %
5.91 %
5.76 %
5.70 %
5.65 %
5.56 %
5.41 %
5.44 %
5.57 %
5.43 %
5.47 %
5.42 %
5.35 %
5.53 %
Others
16.60 %
16.38 %
17.05 %
17.90 %
19.09 %
19.64 %
21.01 %
20.63 %
20.58 %
20.12 %
3.51 %
22.13 %
3.53 %
3.44 %
3.46 %
3.46 %
3.45 %
3.42 %
3.20 %
No of Share Holders
0
7,09,045
7,57,366
6,75,908
6,80,800
6,62,384
6,47,167
6,43,512
6,25,252
6,24,561
6,16,588
6,12,626
6,31,392
6,73,217
6,57,317
6,89,623
7,04,983
7,23,770
7,43,877

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3.5 2 2.75 4 7.5 10 11.5 13.5 16
Dividend Yield (%) 0.00 0.71 0.42 0.78 0.67 0.82 1.01 0.71 0.78 0.91

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
10 Feb 2021 DIVIDEND Dividend
₹ 5.50 /share
 09 Feb 2021 564.35 623.60
25 Aug 2021 DIVIDEND Dividend
₹ 2.00 /share
 23 Aug 2021 703.80 771.35
10 Feb 2022 DIVIDEND Dividend
₹ 7.00 /share
 09 Feb 2022 827.35 886.45
22 Aug 2022 DIVIDEND Dividend
₹ 3.00 /share
 19 Aug 2022 903.90 901.35
08 Feb 2023 DIVIDEND Dividend
₹ 7.50 /share
 08 Feb 2023 1,050.90 1,005.65
28 Jul 2023 DIVIDEND Dividend
₹ 4.00 /share
 28 Jul 2023 945.00 1,134.95
09 Feb 2024 DIVIDEND Dividend
₹ 8.50 /share
 09 Feb 2024 1,371.60 1,500.25
12 Jul 2024 DIVIDEND Dividend
₹ 5.00 /share
 12 Jul 2024 1,541.15 1,583.25
05 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 05 Aug 2024 1,520.65 1,731.65
28 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 28 Oct 2024 1,916.85 1,860.40
21 Jan 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
 21 Jan 2025 1,806.20 1,778.25
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jan 2025 1,756.85 1,739.10
06 Feb 2025 DIVIDEND Dividend
₹ 10.50 /share
 06 Feb 2025 1,739.10 1,753.40
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 22 May 2025 1,744.85 1,731.60
07 Jul 2025 DIVIDEND Dividend
₹ 5.50 /share
 07 Jul 2025 1,731.60 1,676.65
31 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jul 2025 1,663.15 1,734.95
31 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 31 Jul 2025 1,731.60 1,734.95
05 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Nov 2025 1,668.50 1,690.00

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release7 hours ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript6 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 06, 2025
Investor Call Audio RecordingNov 05, 2025
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationNov 05, 2025
Financial Results For The Quarter And Half-Year Ended 30 September 2025Nov 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 15, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025.Oct 14, 2025
ESG Overview For FY 2024-25Oct 14, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementOct 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 24, 2025
Closure of Trading WindowSep 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 18, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Sep 10, 2025
Update On US FDA Inspection At Sun Pharma Halol FacilitySep 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationSep 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Rumour verification - Regulation 30(11)Aug 01, 2025
Clarification sought from Sun Pharmaceutical Industries LtdAug 01, 2025
Sun Pharmas Q1FY26 Investor Call Audio RecordingJul 31, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJul 31, 2025
Financial Results For The Quarter Ended 30 June 2025Jul 31, 2025
Board Meeting Outcome for Outcome Of The Board MeetingJul 31, 2025
Execution Of Settlement Agreement In The In Re Generic Pharmaceuticals Pricing Antitrust LitigationJul 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 15, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Sun Pharma Announces Launch Of LEQSELVI™ In The USJul 14, 2025
Sun Pharma Announces Settlement On LEQSELVI™Jul 14, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Q1 Of FY 2025-26Jul 11, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 10, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 04, 2025
Notice For 33Rd Annual General Meeting Of Sun Pharmaceutical Industries LimitedJul 04, 2025
Reg. 34 (1) Annual Report.Jul 04, 2025
Closure of Trading WindowJun 26, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential India Opportunities Fund Direct - Growth
4.17%
-1808310
-0.94%
-0.91%
Kotak Arbitrage Fund Direct-Growth
0.85%
1759800
0.44%
0.61%
ICICI Prudential Multicap Fund Direct Plan-Growth
1.67%
-1337578
-1.35%
-1.38%
Nippon India Large Cap Fund Direct-Growth
0.56%
619622
0.22%
0.56%
Mirae Asset ELSS Tax Saver Fund Direct-Growth
1.58%
-527485
-0.30%
0.10%
Tata Flexi Cap Fund Direct - Growth
1.99%
424836
1.99%
1.99%
ICICI Prudential Large & Mid Cap Fund Direct Plan-Growth
1.26%
-350000
-0.22%
-0.11%
ICICI Prudential Equity Arbitrage Direct-Growth
0.20%
-290500
-0.13%
-0.20%
Parag Parikh Flexi Cap Fund Direct-Growth
0.11%
287350
0.04%
0.04%
Tata Focused Fund Direct - Growth
2.42%
266758
2.42%
2.42%
DSP ELSS Tax Saver Fund Direct Plan-Growth
1.17%
254905
0.28%
0.26%
UTI Multi Asset Allocation Fund Direct-Growth
1.55%
-228454
-0.57%
-0.73%
ICICI Prudential Focused Equity Fund Direct-Growth
4.97%
-200000
-0.17%
0.31%
NJ Balanced Advantage Fund Direct - Growth
0.71%
-191876
-0.76%
-0.74%
NJ Flexi Cap Fund Direct - Growth
0.96%
-180348
-1.15%
-1.14%
Mirae Asset Large & Midcap Fund Direct-Growth
1.30%
-156486
-0.05%
0.12%
ICICI Prudential Innovation Fund Direct - Growth
2.69%
-150000
-0.29%
0.21%
Sundaram Value Fund Direct-Growth
0.00%
-150000
-1.66%
-1.64%
WhiteOak Capital Flexi Cap Fund Direct - Growth
0.74%
131506
0.34%
0.32%
ICICI Prudential Bharat Consumption Fund Direct - Growth
2.75%
-129133
-0.56%
-0.36%
Baroda BNP Paribas Innovation Fund Direct - Growth
0.00%
-120000
-2.05%
-2.83%
Aditya Birla Sun Life Business Cycle Fund Direct-Growth
0.00%
-114993
-1.07%
-2.17%
ICICI Prudential Equity & Debt Fund Direct-Growth
4.74%
102381
0.14%
0.41%
Aditya Birla Sun Life Large Cap Direct Fund-Growth
1.66%
-100000
-0.01%
-0.02%
Tata Large Cap Direct Plan-Growth
0.00%
-90000
-0.53%
-1.16%

Technical Indicators

RSI(14)
Neutral
71.24
ATR(14)
Less Volatile
27.44
STOCH(9,6)
Neutral
75.27
STOCH RSI(14)
Overbought
95.42
MACD(12,26)
Bullish
3.73
ADX(14)
Weak Trend
24.09
UO(9)
Bearish
55.76
ROC(12)
Uptrend And Accelerating
4.16
WillR(14)
Overbought
-3.22
Bearish
4
Neutral
3
Bullish
2

About Sun Pharmaceutical

Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun Pharma has a strong presence in India and the US, which account for about 70% of its revenue. It operates 43 manufacturing facilities worldwide and invests 7-8% of revenue in R&D annually. The company has expanded through acquisitions and licensing deals to strengthen its specialty and generic portfolios. Key specialty products include Ilumya, Winlevi, Cequa and others in dermatology, ophthalmology and oncology. Sun Pharma supplies medicines to over 100 countries and has manufacturing facilities across six continents.
Website
https://www.sunpharma.com
Chairperson NameDilip S Shanghvi
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104